BioNTech aimed to start mRNA vaccine output in Rwanda in 2025
On Dec. 18, 2023, COVID-19 vaccine maker BioNTech (22UAy.DE) announced that it aims to start production at its…
-
-
Biotechnology | Diagnostics | Disease | Genomics | Neurology | Therapeutics
Alberta researchers revealed full structure of ‘ancient genetic parasite’ implicated in human diseases
On Dec. 14, 2023, the University of Alberta announced that a study published in Nature sheds light on…
-
BioNTech and Australiaﾒs State of Victoria signed agreement on strategic partnership to strengthen mRNA rcosystem
On Dec. 7, 2023, BioNTech announced that it had signed a multi-year strategic partnership with the State of…
-
Japan’s MHLW approved CSL and Arcturus’s self-amplifying mRNA vaccine approved for COVID in adults
On Nov. 28, 2023, CSL and Arcturus Therapeutics announced that Japan’s Ministry of Health, Labor and Welfare (MHLW)…
-
Novavax’s prototype COVID-19 vaccine Nuvaxovid received full approval in Singapore
On Oct. 18, 2023, Novavax announced that Singapore’s Health Sciences Authority (HSA) had granted full approval for Novavax’s…
-
FDA authorized updated Novavax COVID-19 vaccine formulated to better protect against currently circulating variant
On Oct. 3, 2023, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) of…
-
Pfizer and BioNTech received Health Canada authorization for XBB.1.5-adapted monovalent COVID-19 vaccine
On Sept. 28, 2023, Pfizer and BioNTech that Health Canada had authorized the companies’ Omicron XBB.1.5-adapted monovalent COVID-19…
-
Gritstone Bio awarded $433 Mmillion BARDA contract to conduct comparative phase 2b study evaluating next-generation vaccine candidate for COVID-19
On Sept. 27, 2023, Gritstone bio announced that it was awarded a contract by the Biomedical Advanced Research…
-
RNA for the first time recovered from an extinct species
On Sept. 22, 2023, a new study showed the isolation and sequencing of more than a century-old RNA…
-
Pfizer and BioNTech received U.S. FDA approval for 2023-2024 COVID-19 vaccine
On Sept. 11, 2023, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) approved the…
-
COVID-19 | FDA | Infectious Disease | Vaccine
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
On Aug. 30, 2023, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP)…
-
COVID-19 vaccination and boosting during pregnancy benefits pregnant women and newborns
On Aug. 11, 2023, a study funded by the National Institute of Allergy and Infectious Diseases (NIAID) reported…
-
Masters of acclimation: Octopuses adjust to cold by editing their RNA
On Jul. 25, 2023, U.S. National Science Foundation-supported research, led by Joshua Rosenthal of the Marine Biological Laboratory…
-
Scientists recovered RNA expression profiles from extinct Tasmanian tiger
On Jul. 18, 2023, scientists reported that they had extracted, sequenced, and analyzed historical RNA from muscle and…
-
Study raised concerns SARS-CoV-2 evolution outpaces vaccine-generated antibodies
On Apr. 27, 2023, a National Institute of Allergy and Infectious Diseases (NIAID) -led Phase 2 trial compared two…
-
U.S. FDA approved treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene
On Apr. 25, 2023, the U.S. U.S. Food and Drug Administration (FDA announced it had approved Qalsody (tofersen) to…
-
Moderna finalized agreement with Government of the Republic of Kenya to establish an mRNA manufacturing facility
On Mar. 30, 2023, Moderna and the Government of the Republic of Kenya announced they had finalized an…
-
Texas A&M scientists disable protective gene In mosquitoes
On Mar. 15, 2023, scientists at Texas A&M announced that a research study: ‘RNA interference is essential to…
-
Health Canada authorized Moderna’s Omicron-targeting bivalent COVID-19 vaccine in children & Adolescents
On Feb. 17, 2023, Moderna announced that Health Canada had authorized the use of its Omicron-targeting bivalent COVID-19…
-
Large-scale genetic analysis showed microRNAs in human pancreas associated with diabetes
On Feb. 9, 2023, the National Institutes of Health (NIH) announced that a new large-scale genetic analysis found…
-
Moderna announced mRNA-1345, an investigational RSV Vaccine, met primary efficacy endpoints in phase 3 trial
On Jan. 17, 2023, Moderna announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of…
-
BioNTech announced strategic partnership with UK Government to provide up to 10,000 patients with personalized mRNA cancer immunotherapies
On Jan. 5, 2023, BioNTech announced that the Company had signed a Memorandum of Understanding with the Government…
-
BioNTech and Fosun Pharma announced regulatory approval of mono- and bivalent COVID-19 vaccine COMIRNATYﾮ in individuals 12 years and older in Hong Kong
On Dec. 23, 2022, BioNTech and Fosun Pharmaceutical announced that they had received the certificates of registration as…
-
Moderna finalized strategic partnership with UK government
On Dec. 21, 2022, Moderna announced the the finalization of a strategic partnership with the United Kingdom (UK)…
-
EMA Committee for Medicinal Products for Human Use rcommended use of Moderna’s BA.1 bivalent COVID-19 booster in children in the EU
On Dec. 16, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
-
Biotechnology | COVID-19 | FDA | Influenza | Vaccine
Pfizer and BioNTech received U.S. FDA Fast Track Designation for single-dose mRNA-based vaccine candidate against COVID-19 and influenza
On Dec. 9, 2022, Pfizer and BioNTech announced the companies had received Fast Track Designation from the U.S….
-
Moderna received FDA EUA for Omicron-targeting bivalent COVID-19 booster vaccine in children 6 months through 5 years of age
On Dec. 8, 2022, Moderna announced it had received emergency use authorization from the U.S. Food and Drug…
-
Pfizer and BioNTech advancd next-generation COVID-19 vaccine
On Nov. 16, 2022, Pfizer and BioNTech announced that the companies had initiated a Phase 1 study to…
-
Biotechnology | Clinical Research | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine
Moderna’s BA.4/BA.5 targeting bivalent booster, mRNA-1273.222, met primary endpoint
On Nov. 15, 2022, Moderna reported findings from a Phase II/III clinical trial where bivalent Omicron-targeting booster candidates,…
-
Pfizer and BioNTech received positive CHMP opinion for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster for children in EU
On Nov. 10, 2022, Pfizer and BioNTech announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine…
